Loading...
Market
How will IDEAYA's stock change by end of 2025 due to SHR-4849?
3
Resolution / Starting Odds
Increase by more than 20% • 25%
Increase by 0-20% • 25%
Decrease by 0-20% • 25%
Decrease by more than 20% • 25%
Stock market data from financial services such as Bloomberg or Yahoo Finance
Story
IDEAYA Biosciences Licenses SHR-4849 from Hengrui Pharma for $75M, Total Payments Around $1B, Targeting SCLC and NET Tumors
Dec 29, 2024, 11:02 AM
IDEAYA Biosciences has entered into an exclusive licensing agreement with Hengrui Pharma for SHR-4849, a novel drug currently in Phase 1 development. This drug is a DLL3 Topo-I-Payload antibody-drug conjugate (ADC) targeting small cell lung cancer (SCLC) and neuroendocrine tumors (NET). The licensing deal is valued at approximately $75 million, with potential total payments reaching around $1 billion. This move reflects a growing trend where biotechnology companies are increasingly sourcing innovation from China, highlighting the shifting dynamics in the pharmaceutical landscape.
View original story
Similar markets
Stock rises more than 10% • 25%
Stock rises 0-10% • 25%
Stock remains flat or declines 0-10% • 25%
Stock declines more than 10% • 25%
Stock price increases by 10-20% • 25%
Stock price changes by less than 10% • 25%
Stock price decreases • 25%
Stock price increases by more than 20% • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
No significant change or decrease • 25%
Increase by less than 5% • 25%
Shares increase by over 50% • 25%
Shares remain stable • 25%
Shares decrease • 25%
Shares increase by up to 50% • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Above $30 • 25%
Below $10 • 25%
$10-$20 • 25%
$20-$30 • 25%
Stock price increases by 10% to 15% • 25%
Stock price increases by 5% to 10% • 25%
Stock price increases by less than 5% • 25%
Stock price increases by more than 15% • 25%